{"entity":{"id":"nct04644068","kind":"trial","name":"Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","aka":["PETRA"],"tldr":"This study tests a PARP inhibitor; the registry reports that it is active not recruiting.","summary":"The registry lists NCT04644068 as active not recruiting, last updated 2026-09-21. Enrolment is 702 actual participants. Interventions: AZD5305, Paclitaxel, Carboplatin, T- Dxd, Dato-DXd, Camizestrant. Primary measures include The number of subjects with adverse events/serious adverse events; The number of subjects with dose-limiting toxicity (DLT), as defined in the protocol.. No results are posted in the registry; this does not exclude separate publications.","status":"active","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT04644068","url":"https://clinicaltrials.gov/study/NCT04644068"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian","prostate","nsclc","sclc","colorectal"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["saruparib","paclitaxel","carboplatin","trastuzumab-deruxtecan","datopotamab-deruxtecan","camizestrant"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04644068","phase":"1/2","setting":"A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies","sponsor":"AstraZeneca","participation":[{"nct":"NCT04644068","source":"https://clinicaltrials.gov/study/NCT04644068","fetchedAt":"2026-10-07T16:53:24.647Z","studySha256":"7aadcc21fa6245e999641aa1216846e2bfa07c1a98636138631ee3830c26efc6","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-09-21","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"130 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":702,"enrolmentType":"ACTUAL","siteCount":68,"recruitingSiteCount":0,"countries":["Australia","Canada","China","Czechia","Hungary","Italy","Japan","Poland","Russia","South Korea","Spain","Ukraine","United Kingdom","United States"]}],"started":"2020-11-12","startedType":"actual","enrolled":702,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04644068/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"camizestrant","kind":"drug","name":"Camizestrant","route":"/drugs/camizestrant/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"saruparib","kind":"drug","name":"Saruparib","route":"/drugs/saruparib/"},{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}